MiR-1246, a hundreds-fold alteration in microvesicles from three different leukemia cell lines (K562, Nalm-6, and Jurkat), is upregulated to activate the expression of C6orf211 and C19orf10 to promote tumor progression in patients diagnosed as chronic myeloid leukemia [62]. This evidence concerns the gene MYDGF and chronic myelogenous leukemia, BCR-ABL1 positive.